NEW YORK – ARUP Laboratories and Pramana said Tuesday that the firms are partnering on the development of algorithms that will be used to assess complex and difficult-to-scan samples in hematopathology including bone marrow biopsies.
Salt Lake City-based ARUP Laboratories will provide its hematopathologists and annotation tools to train, refine, and validate artificial intelligence-derived algorithms that will be designed and evaluated for use with Cambridge, Massachusetts-based Pramana's SpectralHT whole-slide scanners. The companies said that they also will develop strategies to deploy and distribute advanced diagnostic algorithms.
Financial and other terms of the deal were not disclosed.
"By combining our deep clinical expertise with Pramana's large-scale digitization and AI-driven analysis, we have the ability to develop and clinically validate new AI algorithms that will improve diagnostic accuracy and workflow efficiency," David Ng, medical director for hematologic flow cytometry and applied AI at ARUP Laboratories, said in a statement. "Additionally, this collaboration lays the foundation for the broad distribution of these AI tools, ensuring greater accessibility and impact across the pathology community."
Pramana Chief Product Officer Prasanth Perugupalli added that the collaboration will produce scalable, efficient, and interoperable pathology technologies, and the adoption of advanced diagnostic algorithms can improve precision as well as help to integrate AI-derived insights into lab workflows.
The companies said that the deal is part of an ongoing partnership that reflects their commitments to digital pathology and AI-driven development of pathology tools.